Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study - PubMed (original) (raw)
Multicenter Study
doi: 10.1002/hon.919.
Andrzej Moskwa, Marek Hus, Jarosław Piszcz, Alina Swiderska, Alina Urbanowicz, Małgorzata Całbecka, Justyna Gajkowska, Ilona Seferyńska, Magdalena Hałasz, Dariusz Woszczyk, Miroslaw Markiewicz, Sławomira Krzemień
Affiliations
- PMID: 19728396
- DOI: 10.1002/hon.919
Multicenter Study
Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study
Grzegorz Helbig et al. Hematol Oncol. 2010 Jun.
Abstract
A small subgroup of patients with hypereosinophilic syndrome (HES) demonstrates imatinib-sensitive fusion transcript-the FIP1L1-PDGFRA (F/P+). These cases are currently diagnosed as chronic eosinophilic leukaemia (CEL). In this paper, we screened 77 patients to estimate the frequency of FIP1L1-PDGFRA transcript among patients with unexplained, long-term hypereosinophilia exceeding 1.5 x 10(9)/L and to analyse the clinical and serological features in F/P+ CEL population. The FIP1L1-PDGFRA chimeric protein was detectable in 16 (14 males and 2 females) out of 77 examined HES patients (20%) by RT-PCR. Two patients suffered from cough at diagnosis. Three out of 16 (18%) patients had no organ involvements, in 5-one organ was affected and in the remaining eight cases-at least two. Eosinophilic organ damage/dysfunction identified splenomegaly in the majority of studied patients. We compared clinical and serological features between CEL F/P+ (n = 16) and HES (n = 61) patients. F/P+ cases had significantly increased WBC and absolute eosinophil count (AEC) at diagnosis (p = 0.008 and 0.02), whereas platelet count was decreased in this population (p = 0.03). Serum B12 and tryptase levels were increased (p = 0.002 and 0.004) in CEL F/P+ patients when compared to HES cases whereas serum IL-5 levels were significantly increased in the latter group (p = 0.01). Male gender and splenomegaly occurred more frequent in CEL F/P+ population (p = 0.002 and 0.0007, respectively). Additionally, patients with F/P+ CEL (n = 16) were compared with F/P- CEL (n = 8). The latter group, was significantly older, had lower AEC and higher platelet count. In conclusion, significant clinical symptoms are infrequent present and splenomegaly remains the most common organ involvement in patients with CEL expressing F/P fusion transcript. Our study confirmed the long-term remission on imatinib in this patient population.
(c) 2009 John Wiley & Sons, Ltd.
Similar articles
- The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R, Specchia G, Cuneo A, Beacci D, Nozzoli C, Luciano L, Aventin A, Sambani C, Testoni N, Foppoli M, Invernizzi R, Marynen P, Martelli MF, Mecucci C. La Starza R, et al. Haematologica. 2005 May;90(5):596-601. Haematologica. 2005. PMID: 15921374 - Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
Vandenberghe P, Wlodarska I, Michaux L, Zachée P, Boogaerts M, Vanstraelen D, Herregods MC, Van Hoof A, Selleslag D, Roufosse F, Maerevoet M, Verhoef G, Cools J, Gilliland DG, Hagemeijer A, Marynen P. Vandenberghe P, et al. Leukemia. 2004 Apr;18(4):734-42. doi: 10.1038/sj.leu.2403313. Leukemia. 2004. PMID: 14973504 - A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
Helbig G, Stella-Hołowiecka B, Majewski M, Całbecka M, Gajkowska J, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Hołowiecki J. Helbig G, et al. Br J Haematol. 2008 Apr;141(2):200-4. doi: 10.1111/j.1365-2141.2008.07033.x. Epub 2008 Feb 26. Br J Haematol. 2008. PMID: 18307562 Clinical Trial. - FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
Cools J. Cools J. Verh K Acad Geneeskd Belg. 2005;67(3):169-76. Verh K Acad Geneeskd Belg. 2005. PMID: 16089297 Review. - The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutré SE. Gotlib J, et al. Blood. 2004 Apr 15;103(8):2879-91. doi: 10.1182/blood-2003-06-1824. Epub 2003 Nov 20. Blood. 2004. PMID: 15070659 Review.
Cited by
- [Eosinophilia: hypereosinophilic syndrome vs. eosinophilic granulomatosis with polyangiitis].
Holle JU, Moosig F. Holle JU, et al. Z Rheumatol. 2023 May;82(4):307-320. doi: 10.1007/s00393-023-01345-2. Epub 2023 Apr 26. Z Rheumatol. 2023. PMID: 37099180 German. - PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.
Kaplan HG, Jin R, Bifulco CB, Scanlan JM, Corwin DR. Kaplan HG, et al. Oncologist. 2022 Aug 5;27(8):e661-e670. doi: 10.1093/oncolo/oyac072. Oncologist. 2022. PMID: 35472244 Free PMC article. - GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo.
Wang Y, Zhang L, Tang X, Luo J, Tu Z, Jiang K, Ren X, Xu F, Chan S, Li Y, Zhang Z, Ding K. Wang Y, et al. Transl Oncol. 2020 Apr;13(4):100766. doi: 10.1016/j.tranon.2020.100766. Epub 2020 Apr 1. Transl Oncol. 2020. PMID: 32247263 Free PMC article. - Mechanisms of glucocorticoid resistance in hypereosinophilic syndromes.
Stokes K, Yoon P, Makiya M, Gebreegziabher M, Holland-Thomas N, Ware J, Wetzler L, Khoury P, Klion AD. Stokes K, et al. Clin Exp Allergy. 2019 Dec;49(12):1598-1604. doi: 10.1111/cea.13509. Epub 2019 Oct 27. Clin Exp Allergy. 2019. PMID: 31657082 Free PMC article. Clinical Trial. - A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31).
Iriyama N, Takahashi H, Naruse H, Miura K, Uchino Y, Nakagawa M, Iizuka K, Hamada T, Hatta Y, Nakayama T, Takei M. Iriyama N, et al. Mol Genet Genomic Med. 2019 Apr;7(4):e00591. doi: 10.1002/mgg3.591. Epub 2019 Jan 29. Mol Genet Genomic Med. 2019. PMID: 30697976 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous